[144] ResMed Inc. SEC Filing

Rhea-AI Filing Summary

Ceribell, Inc. (Nasdaq: CBLL) submitted a Form 8-K to disclose a material legal development dated 7 July 2025. The filing states that the company has filed complaints with both the U.S. International Trade Commission and the U.S. District Court for the District of Delaware against Natus Medical Incorporated and certain subsidiaries. Ceribell alleges that Natus is infringing six Ceribell patents covering key elements of the Ceribell EEG headband and electrode design and is engaging in unfair competition. A copy of the related press release is included as Exhibit 99.1 and incorporated by reference. No financial statements, guidance, or earnings metrics are provided in this report.

The 8-K limits its disclosure to the existence of the complaints, the forums in which they were filed, and the patents’ connection to “important features” of the company’s EEG technology. No information is given regarding potential damages sought, litigation timetable, or expected financial impact. The report contains no other business updates under Item 8.01 and lists only the press release and cover-page XBRL file under Item 9.01.

Positive

• Assertive IP protection: Ceribell is proactively defending six key patents tied to its EEG headband and electrode technology.
• Strategic venue selection: Parallel complaints in the ITC and Delaware District Court demonstrate a comprehensive legal strategy.

Negative

• Legal uncertainty: Initiation of litigation introduces potential risks and costs until the dispute is resolved.

Insights

Intellectual-Property Analyst

TL;DR: Ceribell launches dual ITC & federal actions to defend six core EEG patents; immediate disclosure but no financial details.

The company’s 8-K reveals a concentrated effort to protect proprietary headband and electrode designs through simultaneous proceedings in two powerful venues, signalling management’s view that these six patents are central to its competitive positioning. While the filing stops short of quantifying exposure or remedies, the choice of the ITC suggests a desire for rapid relief alongside traditional federal litigation. Because the report provides no earnings or guidance changes, the market must gauge impact purely from the strategic importance of the protected technology and the potential operational distraction of a patent dispute.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	8009	2056075.99	146627399	07/07/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/07/2025	Option Granted - 11/14/2018	Issuer			8009	07/07/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	04/07/2025	8009	1680699.06
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	05/07/2025	8009	1948003.44
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	06/09/2025	8009	2011909.65

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Ceribell (CBLL) file an 8-K on 7 July 2025?

To disclose that the company filed patent-infringement and unfair-competition complaints against Natus Medical.

How many patents does Ceribell allege are being infringed?

The complaints cite six Ceribell patents related to EEG headband and electrode design.

Where were the complaints against Natus Medical filed?

With the U.S. International Trade Commission and the U.S. District Court for the District of Delaware.

What product area is covered by the disputed patents?

Important features of Ceribell’s EEG headband and electrode design.

Where can investors read the full press release?

It is attached to the 8-K as Exhibit 99.1 dated 7 July 2025.